Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/13/22 → 4/19/24 |
Funding
- Alexion Pharmaceuticals: $41,857.00
ALXN2050-MG-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis
- Mahuwala, Zabeen (PI)